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Objectives. We sought to assess whether high dose estrogen
treatment is associated with enhanced arterial reactivity in ge-
netic males.
Background. Although estrogens have been shown to enhance
arterial reactivity in women, and are thereby thought to confer
cardiovascular benefit, the vascular effects of long-term estrogen
therapy in genetic males is unknown.
Methods. We studied the arterial physiology of 30 genetic
males—15 male to female transsexuals receiving long-term high
dose estrogen therapy and 15 healthy male control subjects
matched for age, smoking history and vessel size. Using external
vascular ultrasound, brachial artery diameter was measured at
rest, after flow increase (causing endothelium-dependent dila-
tion [EDD]) and after nitroglycerin (GTN), an endothelium-
independent dilator. Blood pressure, cholesterol and testosterone
levels were also measured in each subject.
Results. Total testosterone and free testosterone index levels
were lower in the transsexuals compared with the control subjects
(p < 0.001). In contrast, EDD was significantly higher in the
transsexuals than in the control males (mean [6SD] 7.1 6 3.1%
vs. 3.2 6 2.8%, p 5 0.001), as was the GTN response (21.2 6 6.7%
vs. 14.6 6 3.3%, p 5 0.002). Total and high density lipoprotein
cholesterol, blood pressure levels and baseline vessel size were
similar in the two groups. On multivariate analysis, enhanced
EDD was associated independently with estrogen therapy (p 5
0.02) and with low total cholesterol (p 5 0.04). An enhanced GTN
response was also significantly associated with estrogen therapy
(p 5 0.03).
Conclusions. Long-term treatment with high dose estrogens is
associated with enhanced arterial reactivity in genetic males,
which may be due to the effects of estrogen excess or androgen
deprivation, or both.
(J Am Coll Cardiol 1997;29:1432–6)
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Women of all ages have a lower risk of cardiovascular mor-
bidity and mortality than do men (1,2). There are now over 30
epidemiologic studies supporting a beneficial effect of endog-
enous and administered estrogen on cardiovascular risk reduc-
tion in premenopausal and postmenopausal women (3). In
particular, estrogen therapy is associated with improved arte-
rial function in postmenopausal women (4–6). Whether long-
term therapy with estrogens may confer a similar benefit in
genetic males is not yet known.
Recent experimental data have suggested that the benefi-
cial vascular effects of estrogen may occur in female but not in
male animals. Hanke et al. (7) have shown an atheroprotective
effect of administered estrogen on ovariectomized, cholesterol-
fed female rabbits, but they were unable to demonstrate any
reduction in aortic plaque size in male rabbits given identical
therapy, consistent with a gender-specific effect. Furthermore,
basal release of nitric oxide is higher in endothelium-intact
aortic rings from female rabbits compared with male rabbits
(8). Recent human data on short-term parenteral estrogen
administration in men have produced conflicting results: some
investigators have demonstrated that short-term intracoronary
infusion of 17-beta-estradiol attenuates the constrictor re-
sponse to acetylcholine in angiographically diseased coronary
arteries in women but not in men (9), whereas others have
found a favorable effect of estrogen administration in men,
with improvement in coronary vasoreactivity (10).
No studies have yet reported the effects of long-term
estrogen therapy on arterial function in men. We have there-
fore studied arterial endothelial and smooth muscle physiology
in a group of male to female transsexuals receiving long-term
high dose estrogen therapy to investigate the effects of such
therapy on arterial reactivity in a male population.
From the *Department of Cardiology and §The Andrology Unit, Royal
Prince Alfred Hospital, Sydney; †The Heart Research Institute, Sydney; and
‡The Discipline of Reproductive Medicine, The University of Newcastle,
Newcastle, Australia. This work was supported by a grant from the National
Heart Foundation of Australia (NHF). Dr. McCrohon supported by the Univer-
sity of Sydney, Ms. Robinson and Dr. Adams by the NHF and Dr. Celermajer by
The Medical Foundation, University of Sydney.
Manuscript received September 3, 1996; revised manuscript received De-
cember 11, 1996, accepted December 16, 1996.
Address for correspondence: Dr. David Celermajer, University of Sydney,
Department of Cardiology, Royal Prince Alfred Hospital, Sydney, Australia.
E-mail: davidc@card.rpa.cs.nsw.gov.au.
JACC Vol. 29, No. 7
June 1997:1432–6
1432
©1997 by the American College of Cardiology 0735-1097/97/$17.00
Published by Elsevier Science Inc. PII S0735-1097(97)00063-6
Methods
Subjects. We investigated 30 adult genetic males (mean
age 40 6 8 years, range 18 to 61)—15 were consecutively
studied male to female transsexuals who had been on high dose
estrogen therapy for at least 6 months, recruited from special-
ist physicians’ practices and from a transgender community
support organization; and 15 were healthy male control sub-
jects recruited from community volunteers. No subjects had a
history of clinical atherosclerosis, hypertension, diabetes mel-
litus or hyperlipidemia, and none were taking regular cardio-
vascular medications. Age and tobacco smoking history were
carefully matched between the groups owing to the established
influence of these factors on vascular reactivity (11,12). All
subjects gave written, informed consent, and the study was
approved by the appropriate institutional committees on eth-
ical practice.
The 15 healthy male to female transsexuals were 23 to 61
years old and had been receiving high dose oral estrogen
therapy for an average of 5 6 5 years (range 6 months to 21
years) (conjugated equine estrogen, 1.25 to 5 mg/day, in 11
patients; estradiol valerate by depot or orally, or both, in 3
patients; and ethinyl estradiol, 100 mg/day in 1 patient). Seven
patients had also had gender reassignment surgery (involving
bilateral orchidectomy), seven were taking antiandrogen
agents (cyproterone acetate, 100 to 200 mg/day, in 6 patients;
and spironolactone, 100 mg, in 1 patient) and four were taking
progestins (medroxyprogesterone acetate, 5 mg/day), accord-
ing to physician preference. The 15 healthy male control
subjects were 18 to 61 years old and had never taken hormonal
therapy of any kind.
Study design. Each patient had one visit to the study
center, during which a history was taken, supine rest blood
pressure was measured and a nonfasting blood sample was
taken for estimation of total and high density lipoprotein
(HDL) cholesterol (using a Hitachi 747 autoanalyzer; HDL
fraction assayed after precipitation with phosphotungstate-
magnesium), total testosterone (using radioimmunoassay) and
sex hormone binding globulin levels (SHBG) (by immuno-
radiometric assay). The free testosterone index (FTI) was
calculated as 100 3 (testosterone/SHBG).
Arterial reactivity was measured in the right brachial artery
using external vascular ultrasound, as described in detail
elsewhere (13). In brief, endothelium-dependent dilation
(EDD) was measured as the change in arterial diameter during
a condition of reactive hyperemia, and the smooth muscle
dependent response was measured as the change in diameter
after a 400-mg spray of sublingual nitroglycerin (GTN). The
accuracy and reproducibility of this method have recently been
established (14). The degree of hyperemia is calculated from
Doppler-derived flow measurements during the condition
of reactive hyperemia, compared with rest flow (13).
Endothelium-dependent dilation measured in this way is pre-
dominantly due to nitric oxide release by the endothelium (15),
and this response in the brachial artery correlates well with
coronary endothelial function (16). The ratio of endothelium-
dependent compared with endothelium-independent dilation
(EDD/GTN ratio) was also calculated, as described previously
by others (17), to assess whether endothelial function might be
enhanced in the subjects taking estrogens, even after account-
ing for the observed differences in smooth muscle responsive-
ness. Ultrasound analysis was performed in each case by two
independent observers who had no knowledge of each subject’s
identity and the stage of each series of scans, as reported
previously (13).
Statistics. Descriptive data are expressed as mean value 6
SD. The two groups of subjects (transsexuals and control
subjects) were compared by independent sample t tests. The
prospectively defined primary end points of this study were
EDD and GTN response. All other t test results were adjusted
for multiple comparisons using Hochberg’s modification of the
Bonferroni procedure (18). The determinants of EDD and
GTN-induced dilation were assessed by univariate and multi-
variate linear regression analyses, with age, total cholesterol,
vessel size, smoking history, systolic blood pressure, degree of
hyperemia and estrogen therapy being entered as the indepen-
dent variables. Statistical significance was inferred at a two-
sided p value ,0.05.
Results
Baseline characteristics (Table 1). The male to female
transsexuals and the control subjects were well matched for
Abbreviations and Acronyms
EDD 5 endothelium-dependent dilation
FTI 5 free testosterone index
GTN 5 glyceryl trinitrate (nitroglycerin)
HDL 5 high density lipoprotein
SHBG 5 sex hormone-binding globulin
Table 1. Baseline Characteristics of 30 Genetic Males Studied






Age (yr) 40 6 11 40 6 13 0.92
Smoking† 8/15 8/15 —
Testosterone (nmol/liter) 1.1 6 0.9 18 6 7 , 0.001
SHBG (nmol/liter) 110 6 88 38 6 17 0.07
FTI (%) 2.3 6 2.8 51 6 21 , 0.001
Total cholesterol (mmol/liter) 4.9 6 0.7 5.2 6 1.0 0.78
HDL cholesterol (mmol/liter) 1.2 6 0.3 1.2 6 0.4 0.92
Vessel size (mm) 4.0 6 0.4 4.2 6 0.4 0.61
SBP (mm Hg) 124 6 17 121 6 12 0.92
DBP (mm Hg) 79 6 7 73 6 7 0.22
*p values adjusted for multiple comparisons (see Methods). †Refers to a
history of active or passive smoke exposure (see Results). Data are presented as
mean value 6 SD or number of subjects. DBP 5 diastolic blood pressure; FTI 5
free testosterone index; HDL 5 high density lipoprotein; SBP 5 systolic blood
pressure; SHBG 5 sex hormone binding globulin.
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age, smoking history, cholesterol levels, blood pressure and
rest vessel size. As expected, both total testosterone and FTI
levels were significantly lower in those subjects taking estro-
gens. Levels of SHBG tended to be higher in the transsexuals
compared with the control subjects (p 5 0.07), consistent with
high dose estrogen therapy. Of the eight subjects in each group
with a history of smoke exposure, five were current smokers
($10 pack-years), two were former smokers ($10 pack-years)
and one had ongoing heavy passive smoke exposure (.1 h/day
for .2 years).
Arterial reactivity studies (Table 2). The degree of reactive
hyperemia was $500% in each group of subjects. In response
to this increase in flow, EDD was significantly higher in the
estrogen-treated patients compared with the control subjects
(7.1 6 3.1% vs. 3.2 6 2.8%, p 5 0.001). Endothelium-
dependent dilation was similar in those transsexual subjects
who had or had not undergone gender reassignment surgery
(p 5 0.08). In addition, the GTN-induced dilator response was
also higher in the transsexual group (21.2 6 6.7% vs. 14.6 6
3.3%, p 5 0.002). The EDD/GTN ratio was also significantly
higher in the estrogen-treated patients (0.34 6 0.11 vs. 0.22 6
0.18, p 5 0.037) (Fig. 1). Neither the EDD nor the GTN
responses were significantly related to the duration of estrogen
treatment in the transsexual subjects (p . 0.25). On multivar-
iate analysis, enhanced EDD was significantly associated with
estrogen therapy (partial r 5 0.42, p 5 0.02) and total
cholesterol level (partial r 5 20.45, p 5 0.04), but not with age,
blood pressure, smoking history, degree of hyperemia or vessel
size (p . 0.20). An enhanced GTN response was also associ-
ated with estrogen therapy (partial r 5 0.44, p 5 0.03), but not
with cholesterol levels or any of the other variables measured.
Discussion
In this study, we have found evidence of enhanced endo-
thelial function (suggested by the higher EDD/GTN ratio) in
genetic males taking high dose estrogen therapy. In addition,
smooth muscle dilator responses to both endothelium-derived
nitric oxide (as tested by EDD) (15) and to an exogenous
source of nitric oxide (as tested by the GTN response) were
also enhanced in the subjects taking estrogens. Because abnor-
malities in the vasodilator responses of arterial endothelial and
smooth muscle cells are important both in the early stages of
atherosclerosis (13,19) and in determining the dynamic behav-
ior of advanced atherosclerotic plaques (20), these estrogen-
related changes in arterial reactivity may be of pathophysio-
logic benefit in these subjects. Caution must be applied to this
interpretation, however, as previous data demonstrate that
high dose estrogens may be prothrombotic in elderly men (21).
As female gender is associated with decreased cardiovascu-
Table 2. Arterial Study Results in 30 Genetic Males Investigated




EDD (%) 7.1 6 3.1 3.2 6 2.8 0.001
GTN (%) 21.2 6 6.7 14.6 6 3 0.002
EDD/GTN 0.34 0.22 0.037
Hyperemia (%) 514 6 145 500 6 249 0.92
Data are presented as mean value 6 SD or ratio. EDD 5 endothelium-
dependent dilation; GTN 5 nitroglycerin-induced dilation.
Figure 1. Endothelium-dependent dilation (EDD), dilator response to
nitroglycerin (GTN) and the EDD/GTN ratio (mean 6 SEM) were all
significantly higher in the transsexual subjects compared with the
control subjects.
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lar risk throughout life, especially before menopause, estrogen
has been proposed as a protective factor. This hypothesis has
been supported by numerous epidemiologic and experimental
studies (3–6). Such benefit may be due to estrogen’s effects on
lipids (22,23) and/or to direct effects on arterial function (4–6).
Although estrogens may be “cardioprotective” in females,
information on any similar benefit on arterial physiology in
men has previously been unavailable, as there are relatively
few men receiving estrogen therapy.
Mechanism of benefit. In this study, the enhanced arterial
reactivity observed in the male to female transsexuals may be
due to estrogen therapy itself. Estrogen receptors are ex-
pressed in endothelial (24) and smooth muscle cells (25). In
women, although some estrogen-related benefit is mediated by
favorable changes in the lipid profile (26), both short- (4,5,27)
and long-term estrogen therapy (6,28) are associated with
improved arterial function. Benefits at both an endothelial and
smooth muscle level have been demonstrated (4,5). Recent
experimental findings have suggested, however, that similar
benefits may not occur in men, at least in the context of
short-term parenteral estrogen therapy in men undergoing
coronary angiography. Collins et al. (9) have shown that
short-term intracoronary administration of estradiol in humans
converted acetylcholine-induced arterial vasoconstriction to
relaxation in the atherosclerotic arteries of women but not of
men. Similar gender-specific effects of estrogen have been
reported in ovariectomized rabbits (7). Reis et al. (10), how-
ever, have recently demonstrated an improvement in vasore-
activity with short-term estrogen administration in men with
angiographically smooth coronary arteries.
In this current study, by contrast, beneficial vascular effects
of estrogens were observed in asymptomatic men without signs
or symptoms of coronary artery disease who were taking
long-term hormonal therapy. The mechanism of improved
EDD may be due to either estrogen-related enhancement of
endothelial nitric oxide production (29) or to antioxidant
effects of estrogens (30), or both, with consequently decreased
levels of oxygen-derived free radicals in the vessel wall and thus
enhanced nitric oxide bioavailability. It is also possible that
some estrogen-related benefits may occur at the smooth mus-
cle level. Estrogen’s effects may also be mediated through
nonestrogen receptor pathways; for example, estrogen may
lower cholesterol levels by stimulating low density lipoprotein
cholesterol clearance by the liver, partially by means of the
asialoglycoprotein receptor on hepatocytes, rather than by
specific estrogen receptors (31).
The observed improvement in arterial reactivity in our
estrogen-treated patients may also be related to androgen
deprivation to castrate levels, rather than to direct estrogen
effects. Androgen deprivation in this context is primarily due to
feedback inhibition of testosterone production through the
hypothalamus and pituitary, or it may be due to bilateral
orchidectomy in some subjects. The additional role of antian-
drogen treatment in the setting of castrate testosterone levels
is probably negligible. We have recently found that androgen
deprivation to castrate levels is also associated with signifi-
cantly enhanced EDD in older men being treated for prostate
cancer, compared with control subjects (32). Because these
older men with androgen deprivation had no enhancement in
GTN response, it is possible that the beneficial effect on
endothelium-independent dilation seen in the transsexual
group in the current study may be more likely related to a
direct smooth muscle effect of high dose estrogen. Similar
effects of supraphysiologic doses of estrogen at the smooth
muscle level have also been demonstrated in other investiga-
tions (4,33).
In this study, hormone-related changes in total and HDL
cholesterol were not observed—that is, these lipid levels were
similar in the transsexuals and control subjects. Therefore,
major estrogen-related alterations in the lipid profile were
unlikely to have contributed to the observed vascular reactivity
differences between the transsexual and control subjects.
There was, however, an inverse relation between total choles-
terol level and EDD when all subjects were considered to-
gether, as we have previously found (34).
Study limitations. A limitation of this study is its cross-
sectional, nonrandomized nature. Therefore, although subjects
were closely matched for known vascular risk factors, such as
age and cigarette smoking, it is possible that unmeasured
differences between the groups may have been present. The
fact that over half of the control subjects had a history of
significant smoke exposure, and several were .45 years old,
accounts for the relatively low EDD observed in the control
group (11,12). A prospective study of the effects of long-term
estrogen therapy in men would be difficult to conduct owing to
the limited access to transsexuals who have not already re-
ceived treatment and to the sensitivities in recruiting and
investigating men during their transition from the male to
female phenotype. Another limitation is the complex hor-
monal effects involved in transsexuality, and therefore uncer-
tainty remains as to the relative contribution of estrogen excess
versus androgen deprivation in producing the observed
changes in vascular function.
Conclusions. This study demonstrates that arterial endo-
thelial and smooth muscle cell dilator responses are signifi-
cantly enhanced in male to female transsexuals compared with
healthy men. These data are consistent with a beneficial effect
of estrogen therapy in the arteries of genetic male subjects.
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